Advances in Managing Metastatic Non-small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors | NCODA

Advances in Managing Metastatic Non-small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors

Read

Eve Segal, PharmD, BCOP

Lead Clinical Pharmacist, Hematology/Oncology

Seattle Cancer Care Alliance

Seattle, Washington

Attachments

NSCLC-Checkpoint-Inhibitors_Segal_PTCE-NCODA_Final-for-Handout-002.pdf

Passion for Patients

315-655-4640
contact@ncoda.org